We recently compiled a list of the Jim Cramer Discusses These 11 Stocks & Finds Few Reasons To Sell. In this article, we are ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian.

American pharmaceutical giant Merck Sharp & Dohme, known as MSD, said Tuesday it is suspending supplies of its human papillomavirus vaccine (HPV) Gardasil to the Chinese market from this month. The ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical giant’s CEO mentioned this in the Q4 earnings call ...

Merck MRK-N said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year forecast ...

De­spite un­cer­tain­ty around HPV vac­cine sales in Chi­na, Mer­ck CEO Rob Davis said he’s con­fi­dent the com­pa­ny can “de­liv­er strong growth” and nav­i­gate Keytru­da ...

Courtney Breen, senior analyst of U.S. biopharmaceuticals at Bernstein, discusses Merck's slump in the market following its halt of Gardasil and HPV vaccine shipments in China. February 04, 2025 at ...

Management expects mid-to-high single-digit growth in Merck's total business outside of GARDASIL China in 2025, supported by increasing momentum in new product launches such as WINREVAIR and ...

Shares in Merck – known outside North America as MSD – tumbled after the drugmaker said it was halting shipments of a top-selling vaccine to China to help a key local supplier reduce excess ...

The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, into China beginning in February and going through at least mid-2025.